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On the basis of the results of recent clinical phase III trials, epidermal growth factor receptor (EGFR) mutations have emerged as the strongest predictor of response to 
EGFR-tyrosine kinase inhibitor (TKI) treatment. Most trials examined a limited number 
of EGFR mutations, as summarized in Table 1.1–6 Association with drug-sensitivity is the 
strongest for the two major hotspots or classical mutation sites, including the point mutation 
at codon 858 in codon 21 (L858R) and the in-frame deletions in exon 19, which account for 
more than 90% of mutations.
In contrast to data on these hotspot mutations, data on the remaining 10% of muta-
tions is less clear. In-frame exon 20 insertions, constituting 4% to 9% of EGFR-TKI muta-
tions, are reported to have baseline resistance to EGFR-TKI treatment. Exon 20 T790M 
mutations are associated with acquired resistance to treatment but can rarely be found in 
combination with classical mutations in primary lung cancers independent of EGFR-TKI 
treatment. G719X and L861Q substitutions seem to be associated with sensitivity, but these 
are relatively infrequent. The efficacy of EGFR-TKIs for treating other uncommon muta-
tions or doubly mutant tumors has not been fully elucidated. As noted in the following letter 
from Sharma et al., we also encourage the sharing of such therapeutic experiences gained 
by treating patients with uncommon EGFR mutations in the “Letters to the Editor” section. 
In such a letter, the author(s) should include the following information that will help when 
considering treatment for other patients with such mutations:
1. Basic clinicopathological features (histological subtype, smoking status, performance 
status, sex, ethnicity, and disease stage).
2. Assay methods for detecting EGFR mutations (dideoxynucleotide sequencing, 
SNaPshot, Sequenom, etc). When direct sequencing is used, both forward and reverse 
sequencing traces should show the identical mutation.
3. Primary EGFR mutation (L858R, Exon 19 del, G719X, L861Q, Exon 20 ins, and 
T790M).
4. Secondary or additional EGFR mutations.
5. Type of EGFR TKI used for treatment, such as gefitinib or erlotinib.
6. EGFR-TKI line (details of chemotherapy treatments, if administered, pre- or post-
EGFR TKI).
7. Response according to the criteria of Response Evaluation Criteria In Solid Tumors, 
and maximum tumor-reduction rate.
8. Progression free and overall survival periods.
9. Reference detailing whether or not the patient has been previously reported in any 
publication, either as a single case or as a part of many cases.
The varying efficacy of TKIs for treating gastrointestinal stromal tumors with specific muta-
tions is well known, for which therapeutic strategies and dosages are adjusted accordingly. 
Lung cancer treatment may follow in such a personalized manner.7 Indeed, after introducing 
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third-generation EGFR-TKIs, agents and/or dosages may be 
adjusted according to the types and sites, particularly in cases 
with uncommon mutations.
The data will be incorporated into Vanderbilt’s DNA-
mutation inventory to refine and enhance cancer treatment 
database, which is a catalogue of clinically relevant somatic 
mutations in lung cancer created to aid physicians within the 
clinic in their selection of therapies for patients with various 
mutations and lung cancer.8 Although this project has been 
started with patients with known EGFR mutations (currently 
with more than 1600 individual patient-level entries), the pro-
gram will eventually expand to incorporate all known cancer 
mutations with potential clinical significance. Database requests 
can be made online at MyCancerGenome (www.mycancerge-
nome.org/DIRECT), Vanderbilt’s web-based tool designed to 
enable a genetically-informed approach to cancer medicine.
REFERENCES
 1. Mok TS, Wu YL, Yu CJ, et al. Gefitinib or carboplatin-paclitaxel in 
pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
 2. Lee JS, Park K, Kim SW. A randomized phase III study of gefitinib 
versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line 
treatment for neversmokers with advanced or metastatic adenocarcinoma 
of the lung. The13th World Conference on Lung Cancer. San Francisco: 
2009:Abstr PRS.4. Available at http://www.asco.org/ASCov2/Meetings/
Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82662. 
Accessed April 2, 2012.
 3. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell 
lung cancer harbouring mutations of the epidermal growth factor receptor 
(WJToG3405): an open label, randomised phase 3 trial. Lancet Oncol 
2010;11:121–128.
 4. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med 2010;362:2380–2388.
 5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line 
treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (oPTIMAL, CToNG-0802): a multicentre, open-label, 
randomised, phase 3 study. Lancet Oncol 2011;12:735–742.
 6. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemo-
therapy (CT) in advanced non-small cell lung cancer (NSCLC) 
patients (p) with epidermal growth factor receptor (EGFR) mutations: 
Interim results of the European Erlotinib Versus Chemotherapy 
(EURTAC) phase III randomized trial. 2011 ASCo Annual Meeting. 
Chicago: 2011 J Clin Oncol 2011 29:(suppl; abstr 7503). Available 
at http://www.asco.org/ASCov2/Meetings/Abstracts?&vmview=abst_
detail_view&confID=102&abstractID=78285. Accessed April 2, 
2012.
 7. Sharma A, Tan TH, Cheetham G, Scott HS, Brown MP. Rare and novel 
epidermal growth factor receptor mutations in non-small cell lung cancer 
and lack of clinical response to gefitinib in two cases. J Thoracic Oncology 
2012;7:941–942.
 8. Horn L, Chen H, Lovly CM, Andrews J, Yeh P, Levy MA, Pao W. DIRECT: 
DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A 
catalogue of clinically relevant somatic mutations in lung cancer. J Clin 
Oncol 2011 29: (Suppl; abstr 7575). Available at http://www.asco.org/
ASCov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10
2&abstractID=82662. Accessed April 2, 2012.
TABLE 1. Phase III Clinical Trials Using EGFR TKIs
Author Study
N (EGFR  
mut/total) Methods Sites Examined
Mok et al.1 IPASS 132 Scopion ARMS L858R, L861Q, S768I, G719X, exon 20 ins, and exon 19 del,
Lee et al.2 First-SIGNAL 27 Not available L858R and exon 19 del
Mitsudomi et al.3 WJToG 3405 172/172 Cycleave PCR and others L858R and exon 19 del
Maemondo et al.4 NEJGSG002 228/228 PNA-LNA clamping L858R, L861Q, G719X, and exon 19 del,
Zhou et al.5 oPTIMAL 154/154 Cycleave PCR L858R and exon 19 del
Rosell et al.6 EURTAC 174/1227 taqman PCR and fragment analysis L858R and exon 19 del
TKI, tyrosine kinase inhibitor; PCR, polymerase chain reaction; EGFR, endothelial growth factor receptor.
